Filing Flows › Biodesix (BDSX) › Q3 2026 › vs Q2 2026
Biodesix (BDSX) Q3 2026 vs Q2 2026 (quarter over quarter)
Biodesix's revenue fell $2.8M (-10%) from $26.9M in Q2 2026 to $24.0M in Q3 2026. The biggest changes: Diagnostic Tests −$2.3M (-9%); Development Services −$526K (-35%).
Biodesix, Q3 2026: revenue $24.0M (+10% year over year), operating margin -25.4%, net loss $8.0M, operating cash flow −$7.2M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Diagnostic Tests | $23.1M | $25.3M | −$2.3M | -9% |
| Development Services | $986K | $1.5M | −$526K | -35% |
| Revenue | $24.0M | $26.9M | −$2.8M | -10% |
| Net loss | $8.0M | $7.3M | $759K | +10% |
| Costs & expenses | $32.1M | $34.1M | −$2.1M | -6% |
| Operating costs | $30.2M | $32.2M | −$2.1M | -6% |
| Interest & other, net | $1.9M | $1.9M | $35K | +2% |
| Research & development | $3.0M | $3.1M | −$141K | -4% |
| SG&A | $22.5M | $24.3M | −$1.8M | -7% |
| Other operating costs | $4.7M | $4.8M | −$172K | -4% |
| Operating cash sources | $9.5M | $3.8M | $5.7M | +151% |
| Depreciation & amortization | $1.4M | $1.4M | $13K | +0.9% |
| Share-based compensation | $852K | $820K | $32K | +4% |
| Cash used in operations | $7.2M | $1.6M | $5.6M | +361% |
| Net loss absorbed | $8.0M | $7.3M | $759K | +10% |
| Working capital & other | $1.4M | −$3.5M | $4.9M | — |
Questions
How much did Biodesix's revenue grow quarter over quarter in Q3 2026?
Biodesix's revenue fell $2.8M (-10%) from $26.9M in Q2 2026 to $24.0M in Q3 2026.
What drove Biodesix's revenue change in Q3 2026?
Diagnostic Tests −$2.3M (-9%); Development Services −$526K (-35%).